Victor Enrique Ortega MD PhD

Asthma & COPD, Critical Care Medicine

Professor of Medicine, Department of Internal Medicine, Division of Pulmonary Medicine, Center for Individualized Medicine, Mayo Clinic

Join to View Full Profile

13400 E. Shea BoulevardScottsdale, AZ 85259
Phone+1 480-342-3538

Education & Training

Wake Forest University Graduate School of Arts and SciencesPhD, Molecular Medicine and Translational Science, 2010 - 2016
Wake Forest University Baptist Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2006 - 2010
Cleveland Clinic FoundationResidency, Internal Medicine, 2003 - 2005
Cleveland Clinic FoundationInternship, Internal Medicine, 2002 - 2003
Ponce Health Sciences University School of MedicineClass of 2002

Certifications & Licensure

AZ State Medical License 2021 - 2026
NC State Medical License 2006 - 2022
OH State Medical License 2002 - 2008
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Who's Who American Thoracic Society, 2021
Parker B. Francis Research Opportunity Award Francis Family Foundation, 2015
NIH Clinical Research Loan Repayment Program National Center for Advancing Translational Sciences
NIH Clinical Research Loan Repayment Program National Heart, Lung, and Blood Institute
CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012
Second Prize, Oral Presentation Sixth Annual Respiratory Disease Young Investigators’ Forum, Phoenix, AZ
Minority Trainee Travel Award American Thoracic Society
Join now to see all

Clinical Trials

Severe Asthma Research Program
ACTIVE_NOT_RECRUITING
Severe Asthma Research Program - Wake Forest University Start of enrollment: 2012 Dec 01
Completed
Best African American Response to Asthma Drugs Start of enrollment: 2014 Feb 01
Completed
Phase 3
Study of COPD Subgroups and Biomarkers
ACTIVE_NOT_RECRUITING
Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations Start of enrollment: 2014 Jul 01
Completed
Phase 3
Steroids In Eosinophil Negative Asthma Start of enrollment: 2014 Jul 01
Completed
Phase 3
A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects Start of enrollment: 2014 Sep 01
Completed
Phase 3
Alendronate to Prevent Loss of Bronchoprotection in Asthma Start of enrollment: 2015 Jan 01
Completed
Phase 2, Phase 3
EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients Start of enrollment: 2015 Oct 30
Completed
Phase 2
Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs Start of enrollment: 2015 May 05
Completed
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation Start of enrollment: 2015 Nov 01
Completed
Phase 2
Standardized Treatment of Pulmonary Exacerbations II Start of enrollment: 2016 Jun 01
Completed
Phase 4
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) Start of enrollment: 2016 Nov 01
Completed
Phase 3
A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF) Start of enrollment: 2017 May 24
Completed
Phase 3
AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis Start of enrollment: 2017 Sep 20
Completed
Phase 3
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Start of enrollment: 2019 Apr 30
Completed
Phase 2
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype Start of enrollment: 2020 Jan 13
Terminated
Phase 2
Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy Start of enrollment: 2020 Aug 25
COMPLETED
Join now to see all

Publications & Presentations

PubMed

Phenotypes and Trajectories of Tobacco-exposed Persons with Preserved Spirometry: Insights from Lung Volumes.
Mehrdad Arjomandi, Siyang Zeng, Igor Barjaktarevic, Eugene R Bleecker, Russell P Bowler
Annals of the American Thoracic Society. 2025-04-01
Longitudinal Outcomes in Pi*MZ Alpha-1 Antitrypsin Deficient Individuals with Tobacco Smoking History from the SPIROMICS Cohort.
Igor Barjaktarevic, Roxana Hixson, Zian Zhuang, Russell G Buhr, Vickram Tejwani
Annals of the American Thoracic Society. 2025-03-11
Polygenic Risk Score Added to Conventional Case Finding to Identify Undiagnosed Chronic Obstructive Pulmonary Disease.
Jingzhou Zhang, Brian D Hobbs, Edwin K Silverman, David Sparrow, Victor E Ortega
JAMA. 2025-03-04

Journal Articles

Assembly of a Pan-Genome from Deep Sequencing of 910 Humans of African Descent
James G Wilson, Rachel M Sherman, Victor E Ortega, Jean G Ford, Christopher O Olopade, Nadia N Hansel, Olufunmilayo Olopade, Esteban G Burchard, Lorraine B Ware, Tina ..., Nature
A Genome-Wide Association and Admixture Mapping Study of Bronchodilator Drug Response in African Americans with Asthma
Rajesh Kumar, Denise Serebrisky, Pedro C Avila, Esteban G Burchard, Neeta Thakur, Stephen P Peters, Michael A Lenoir, Adam Davis, Harold J Farber, Meghan E McGarry, Je..., Nature

Books/Book Chapters

Precision in Pulmonary, Critical Care, and Sleep Medicine
Chapter: Precision Medicine for All: Minority Health
Page 395 - 407Victor E. Ortega and Juan C. CeledonEditors: Jose L. Gomez, Blanca E. Himes, Naftali Kaminski.Springer Nature, Switzerland2020
Merck Manual Professional Edition
Chapter: Asthma and Related Disorders
Genese G, Ortega VEMerck, Sharp, and Dohme, Kenilworth, NJ2019
Merck Medical Manual
Chapter: Asthma and Related Disorders
Pennington ER, Ortega VEMerck, Sharp, & Dohme, Kenilworth, New Jersey
Personalizing Asthma Management for the Clinician
Chapter: Pharmacogenomics and the Development of Precision Medicine for Asthma Management
Pennington EJ, Ortega, VEEditors: Szefler SJ, Holguin F, Wechsler ME.Saunders Elsevier, Philadelphia, Pennsylvania
Achieving Respiratory Health Equity in the United States
Chapter: The Role of Human Genetics Research and Personalized Medicine in Achieving Respiratory Health Equity.
Page 149 - 172Victor E. Ortega, MD, PhDEditors: Juan C. Celedon, MD, DrPH.Springer Nature, Switzerland2017
Murray and Nadel’s Textbook of Respiratory Medicine
Chapter: Genetics in Asthma and COPD
Page 786 - 806Ortega VE, Bleecker EREditors: Broaddus VC, Mason RJ, Ernst JD, King TE, Lazarus SC, Murray JF, Nadel JA, Slutsky AS, Gotway MB.Saunders Elsevier, Philadelphia, PAEdition 6,2015
Advances in Combination Therapy for Asthma and COPD
Chapter: The safety of long-acting beta-agonists and the development of combination therapies for asthma and COPD
Page 102 - 134Ortega VE, Bleecker EREditors: Jan Lotvall.Wiley-Blackwell, Chichester, West Sussex, UK2011
Join now to see all

Press Mentions

Genetics Pinpoint Undiagnosed COPD CasesFebruary 6th, 2025
Tomorrow’s Cure: Predicting Disease Risk with Polygenic Risk ScoresJanuary 29th, 2025
What’s Your Health Forecast? Expert Explains Science Behind Personal Guides to Well-BeingDecember 16th, 2024
Join now to see all

Grant Support

Gender and AsthmaNational Heart, Lung, and Blood Institute2023–2027
Parker B. Francis Research Opportunity AwardFrancis Family Foundation2015–Present
Therapeutics Development CenterCystic Fibrosis Foundation Therapeutics2014–Present
Effects of Rare Variants and Ancestry on Beta Agonist Response in Asthma and COPDMAYO CLINIC ARIZONA2021–2024
Understanding the Origins of Early COPDNational Heart, Lung, and Blood Institute2019–2024
Non-coding RNA structure change in Chronic Obstructive Pulmonary DiseaseNational Heart, Lung, and Blood Institute2019–2023
Effects of Rare Variants and Ancestry on Beta Agonist Response in Asthma and COPDNational Heart, Lung, and Blood Institute2019–2023
Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) NetworkNational Heart, Lung, and Blood Institute2018–2023
Collaborative Cohort of Cohorts for COVID-19 ResearchNational Heart, Lung, and Blood Institute2020–2022
Combined Cardiopulmonary Failure in COPD: SPIROMICS HFNational Heart, Lung, and Blood Institute2019–2022
SPIROMICS II: Biological Underpinnings of COPD Heterogeneity and ProgressionNational Heart, Lung, and Blood Institute2017–2022
Cystic Fibrosis Adult Care CenterCystic Fibrosis Foundation2012–2019
Mentored Clinical Scientist Research Career Development Award, Parent K08National Heart, Lung, and Blood Institute2015–2018
Career Development Program in the Genetics and Genomics of Lung DiseasesNational Heart, Lung, and Blood Institute2010–2013